TABLE 1.
Demographics and clinical features of infections caused by ST5-MRSA vs ST764-MRSA isolates
| Characteristica | Total (n = 90) | ST5b (n = 44) |
ST764 (n = 46) |
P valuec |
|---|---|---|---|---|
| Demographic | ||||
| Age, years | 69 (51, 80) | 61 (42, 72) | 77 (64, 84) | <0.001 |
| Gender, male | 63 (70.0%) | 29 (65.9%) | 34 (73.9%) | 0.492 |
| Weight, kg | 60 (55, 70) | 65 (55, 72) | 60 (55, 70) | 0.126 |
| BMI, kg/m2 | 22.0 (20.0, 24.0) | 22.8 (20.3, 24.0) | 21.8 (19.0, 24.0) | 0.190 |
| ICU | ||||
| ICU admission | 53 (58.9%) | 22 (50.0%) | 31 (67.4%) | 0.133 |
| ICU stay days | 11(0, 30) | 0 (0, 28.5) | 18 (0, 31) | 0.206 |
| Occurred in tertiary care hospitals | 51 (56.7%) | 39 (88.6%) | 12 (26.1%) | <0.001 |
| Underlying disease | ||||
| Cardiovascular diseases | 31 (34.4%) | 10 (22.7%) | 21 (45.7%) | 0.027 |
| Diabetes | 14 (15.6%) | 5 (11.4%) | 9 (19.6%) | 0.386 |
| Strokes | 33 (36.7%) | 7 (15.9%) | 26 (56.5%) | <0.001 |
| COPD | 3 (3.3%) | 1 (2.3%) | 2 (4.3%) | >0.999 |
| Autoimmune diseases | 1 (1.1%) | 1 (2.3%) | 0 (0%) | 0.489 |
| Trauma | 11 (12.2%) | 3 (6.8%) | 8 (17.4%) | 0.198 |
| Solid tumor | 17 (18.9%) | 10 (22.7%) | 7 (15.2%) | 0.426 |
| Surgery | 39 (43.3%) | 23 (52.3%) | 16 (34.8%) | 0.136 |
| Implant | ||||
| Venous catheter | 64 (71.1%) | 29 (65.9%) | 35 (76.1%) | 0.355 |
| Endotracheal intubation | 30 (33.3%) | 19 (43.2%) | 11 (23.9%) | 0.074 |
| Tracheotomy | 24 (26.7%) | 19 (43.2%) | 5 (10.9%) | 0.001 |
| Urinary catheter | 54 (60.0%) | 30 (68.2%) | 24 (52.2%) | 0.137 |
| Drainage tube | 22 (24.4%) | 11 (25.0%) | 11 (23.9%) | >0.999 |
| Infection site | ||||
| Bloodstream infection | 11 (12.2%) | 7 (15.9%) | 4 (8.7%) | 0.348 |
| Pulmonary infection | 69 (76.7%) | 32 (72.7%) | 37 (80.4%) | 0.459 |
| Central nervous system infections | 3 (3.3%) | 3 (6.8%) | 0 (0%) | 0.113 |
| Skin and soft tissue infections | 5 (5.6%) | 4 (9.1%) | 1 (2.2%) | 0.198 |
| Urinary tract infection | 4 (4.4%) | 1 (2.3%) | 3 (6.5%) | 0.617 |
| Other infection | 6 (6.7%) | 3 (6.8%) | 3 (6.5%) | >0.999 |
| Treatment | ||||
| Vancomycin daily dose, g | 1.8 (1.2, 2.0) | 2 (1.6, 2.1) | 1.4 (1.0, 2.0) | <0.001 |
| Vancomycin duration | 13 (10,18) | 13 (10,17) | 12 (9,20) | 0.399 |
| Combined with β-lactams | 58 (64.4%) | 30 (68.2%) | 28 (60.9%) | 0.514 |
| Combined with rifampin | 7 (7.8%) | 3 (6.8%) | 4 (8.7%) | >0.999 |
| Combined with quinolones | 4 (4.4%) | 3 (6.8%) | 1 (2.2%) | 0.355 |
| Combined with other antibiotics | 25 (27.8%) | 11 (25.0%) | 14 (30.4%) | 0.641 |
a
ST, sequence type; BMI, body mass index; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease.
b
Continuous variables were expressed as median (interquartile range) and categorical variables were summarized as the number of cases (%) in the table.
c
P values< 0.05 are shown in bold.